Co-Investigator(Kenkyū-buntansha) |
IMACHI Kou University of Tokyo, Institute of Medical Electronics, 医学部・医用電子研究施設, 教授 (10010076)
YOON Shin Lee Seoul National University, Dept. of Biomedical Engineering, 生体医工学研究所, 特別研究員
CHEOL Sang Kim Seoul National University, Dept. of Biomedical Engineering, 生体医工学部, 講師 卜級化学研究員
HAN Ik Jo Seoul National University, Dept. of Biomedical Engineering, 附属病院・同医学部・臨床病理学, 教授及び委員長
KYUNG Phil Seo Seoul National University, Dept. of Biomedical Engineering, 小児病院・胸部、循環器外科, 教授及び院長
IN Seon Shin Seoul National University, Dept. of Biomedical Engineering, 生体医工学研究所, 特別研究員
SEON Yang Park Seoul National University, Dept. of Biomedical Engineering, 医学部・内科医学, 准教授
BYOUNGーGOO M 国立ソウル大学, 医学部・生体医工学科・生体医工学研究所, 教授 所長
TAENAKA Yoshiyuki National Cardiovascular Center, Dept. of Artificial Organs, 人工臓器部, 室長 (00142183)
MATSUDA Takehisa National Cardiovascular Center, Dept. of Biomedical Engineering, 生体工学部, 部長 (60142189)
KATO Hisao National Cardiovascular Center, Dept. of Pathology and Ethiology, 病因部, 部長 (80029959)
MIN Byoung-Goo Seoul National University, Dept. of Biomedical Engineering
|
Research Abstract |
Present problems in the development of totally implantable total artificial heart were discussed especially focusing on the antithrombogenesity. In the national cardiovascular center, electrohydraulic type total artificial heart is under development. The merit of this system is that both ventricles can be separately implanted. However, energy loss to reverse the motor rotation is a problem to be solved in this system. To promote the antithrombogenesity of the pump, a novel surface process technology based on surface photoreactive chemistry is also under development. In the university of Tokyo, a unique total artificial heart is under development. This system is composed of a single centrifugal pump (CFP) and two three-way valves. One port of each three-way valve is connected to the inlet and outlet of a CFP, respectively. The other two ports of each valve are connected to the right and left atrium, p ulmonary artery and aorta. The CFP can perfuse the pulmonary and systemic circulation alternately with pulsatile flow by switching the two three-way valves. Blood mixture in the CFP and antithrombogenesity are problems in this system. In Seoul national university, a moving-actuator type total artificial heart is under development. Animal survived for 100 hours with this system. Polymer surface modification with endothelial cells and proteolytic enzyme is being examined to promote antithrombogenesity.
|